Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound
Frank Vinluan / medcitynews - Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing a…
AI Summary: Kailera announced plans for an initial public offering to fund late‑stage development of a Phase 3 obesity candidate licensed from Hengrui, positioning the program as a potential rival to Lilly’s Zepbound. The IPO aims to accelerate clinical work and commercial readiness as investors weigh market appetite for next‑generation weight‑loss therapies.
- Antimicrobial resistance risk found in South African wastewater (1)
- Financing rush: IPOs and venture cash fueling obesity drug race (4)
- New commercial models: subscriptions, telehealth, expanded patient access (4)
- Regulatory wins and science shaping next-generation weight-loss drugs (6)
- All Other Stories
Antimicrobial resistance risk found in South African wastewater
Financing rush: IPOs and venture cash fueling obesity drug race
New commercial models: subscriptions, telehealth, expanded patient access
Regulatory wins and science shaping next-generation weight-loss drugs
All Other Stories
Lost in space: Sperm struggles to navigate during weightless sex
medicalxpress - Scientists have used a tiny plastic "obstacle course" to test how much sperm would struggle to navigate during sex in the weightlessness of space.
AI Summary: New research shows sperm struggle to navigate and function in weightless conditions, suggesting microgravity could impair fertilization and complicate human reproduction beyond low-Earth orbit. Scientists warn these findings raise practical and biological questions for long-duration missions and potential colonization efforts, prompting calls for more reproductive biology studies in space.
J. Michael Bishop, Nobel Prize Winner for Cancer Research, Dies at 90
Delthia Ricks / nytimes - He helped discover cancer-causing genes. Later, as chancellor of the University of California, San Francisco, he led a major expansion.
AI Summary: J. Michael Bishop, Nobel Prize–winning cancer researcher, has died at 90. Colleagues recall his transformative work illuminating oncogenes and reshaping cancer biology, plus a career of mentorship that seeded generations of scientists. The obituaries and memorial pieces celebrate both his landmark discoveries and the enduring institutions and researchers he helped build.
Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
Jess Mador, WABE / kffhealthnews - Thousands of employees are gone and last summer’s shooting resonates still at the Centers for Disease Control and Prevention headquarters and among the large public health community in Atlanta.
AI Summary: An internal crisis at the U.S. Centers for Disease Control has left staff demoralized after a year of firings, funding cuts and a workplace shooting. The acting chief vows to restore stability while the White House delays a permanent director nomination, prompting media scrutiny and debate over agency leadership and morale.
- Demoralized staff and leadership scramble at Atlanta's CDC (3)
- Inside the scramble for a permanent CDC director (3)
- Wider federal research cuts, RSV spread complicate CDC mission (3)
- All Other Stories
Demoralized staff and leadership scramble at Atlanta's CDC
Inside the scramble for a permanent CDC director
Wider federal research cuts, RSV spread complicate CDC mission
All Other Stories
Vivek Subbiah: New Nature Study on Thymic Health and Response
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow published in NATURE journal ‘Thymic health and immunotherapy outcomes in patients […]
AI Summary: A new Nature study reveals that adult thymic health materially affects immune aging and responses to cancer treatment. Researchers show thymic integrity correlates with stronger immune surveillance and better therapy outcomes, reviving interest in thymus-targeted interventions. Experts describe the finding as a necessary reappraisal of an organ long written off by adult medicine — cue the applause.
- Aging immunity: why older immune systems fail us (5)
- Front lines: new targets and tactics in cancer immunotherapy (9)
- On the ground: adult thymus drives longevity and therapy success (5)
- All Other Stories
Aging immunity: why older immune systems fail us
Front lines: new targets and tactics in cancer immunotherapy
On the ground: adult thymus drives longevity and therapy success
All Other Stories
TerraPower Isotopes Invests $450M in Actinium-225 Production Facility
oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…
AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.
What happens to your brain in nature? The neuroscience explained
medicalxpress - Have you ever felt calmer almost as soon as you step into the woods? Or maybe noticed your busy mind soften as you look out at the sea?
AI Summary: Researchers report that immersive time in natural settings produces detectable changes in brain networks tied to attention, emotion regulation and memory. The findings suggest brief nature exposure can recalibrate neural states and boost mental health — science’s polite way of telling you to go outside instead of doomscrolling.
Verily raises $300M, sheds Alphabet’s majority control
Shelby Livingston / endpoints - Verily has raised $300 million in new, outside funding that ends parent company Alphabet's controlling position in the healthcare innovation company, Endpoints News has learned exclusively. The funding round was led by Series X Capital ...
AI Summary: Verily secured a $300 million financing round that reduces Alphabet’s majority control, bringing new strategic investors on board including health system partners. The cash infusion aims to accelerate Verily’s healthcare technology and platform ambitions — because nothing says “healthcare disruption” like another well‑funded pivot.
Engineered tissue offers hope for children born with 'missing' esophagus
medicalxpress - Scientists from Great Ormond Street Hospital (GOSH) and University College London (UCL) have created the first lab‑grown esophagus—the food pipe—shown to safely replace a full section of the organ and restore normal function, including swallowing, in a gr…
AI Summary: Researchers report progress developing lab-grown esophageal tissue to treat children born with congenital absence or severe damage of the esophagus. Early preclinical and surgical work demonstrates that engineered tissue constructs can be implanted and integrated, offering a potential alternative to complex reconstructions — a promising step for tiny patients with very big problems.
Rob Winn Appointed Director of NCI-Designated Fox Chase Cancer Center
oncodaily - Fox Chase Cancer Center shared a post on LinkedIn: “Temple Health – Temple University Health System today announced the appointment of Dr. Rob Winn, MD, as the next Cancer Center […]
AI Summary: Rob Winn has been appointed director of the NCI‑designated Fox Chase Cancer Center, taking the reins of clinical, research and strategic operations. His role will focus on strengthening translational research, patient care integration and institutional partnerships to advance the center's mission — you know, the usual: cure more cancer, argue less in committee meetings.
'Leaky' brain barrier revealed as driver of chronic brain damage in retired combat and collision sports athletes
medicalxpress - Research, led by teams at Trinity College Dublin and the FutureNeuro Research Ireland Center, has pinpointed the mechanism linking some sports injuries to poor brain health in retired athletes. The research, published in Science Translational Medicine, ha…
AI Summary: New research links repetitive head impacts in contact and combat sports to blood–brain barrier breakdown, which appears to drive chronic traumatic encephalopathy and progressive cognitive decline. The studies identify vascular leakage as a key mechanism and suggest that strategies to bolster the barrier could reduce long-term brain damage in athletes and veterans.
Vanderbilt Health president, CEO to retire
Paige Twenter / beckershospitalreview - Jeff Balser, MD, PhD, president and CEO of Vanderbilt Health and dean of Vanderbilt University’s school of medicine, plans to retire from both roles Dec. 31, according to a March 12 news release from the Nashville, Tenn.-based organizations. During his 17…
AI Summary: Jeff Balser, president and CEO of Vanderbilt Health (and dean of Vanderbilt University School of Medicine), will retire at the end of the year, prompting the health system’s board to launch a national search for his successor. Leaders emphasize a careful transition to preserve academic‑clinical stability while navigating complex operational challenges.
Effects of daily multivitamin–multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial
Sidong Li / nature - Nature Medicine, Published online: 09 March 2026; doi:10.1038/s41591-026-04239-3In a prespecified ancillary analysis of the COSMOS randomized trial, supplementation with daily multivitamins, but not with cocoa extract, over the course of 2 years decreased…
AI Summary: A prespecified ancillary analysis of the COSMOS randomized trial found that daily multivitamin–multimineral (with cocoa extract) modestly slowed epigenetic aging clocks over two years. The Nature Medicine report highlights measurable shifts in biomarkers of biological aging, while noting uncertain clinical significance and the need for longer follow-up.
Elizabeth McKenna: New Cancer Grand Challenges Teams Announced
oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]
AI Summary: Global funders announced new Cancer Grand Challenges awards, backing five international teams with large, high‑risk grants to pursue transformative cancer science. The initiative aims to accelerate unconventional, high‑reward projects and foster cross‑disciplinary collaboration — essentially underwriting audacity in hopes that at least one risky bet pays off.